About QBiotics
QBiotics is a company based in Brisbane (Australia) founded in 2000 by Victoria Gordon and Paul Reddell. It operates as a HealthTech. QBiotics has raised $98.07 million across 3 funding rounds from investors including TDM Growth Partners. QBiotics offers products and services including Tigilanol Tiglate, EBC-1013, and STELFONTA. QBiotics operates in a competitive market with competitors including Jazz Pharmaceuticals, Zoetis, Ceva, C4 Therapeutics and Erasca, among others.
- Headquarter Brisbane, Australia
- Founders Victoria Gordon, Paul Reddell
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Qbiotics Group
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$98.07 M (USD)
in 3 rounds
-
Latest Funding Round
$64.42 M (USD), Series C
Jun 25, 2021
- Investors
-
Employee Count
Employee Count
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of QBiotics
QBiotics offers a comprehensive portfolio of products and services, including Tigilanol Tiglate, EBC-1013, and STELFONTA. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Developed as treatment for soft tissue sarcomas oncology.
Designed for treatment of chronic and acute wounds.
Approved for non-resectable mast cell tumors in dogs.
Funding Insights of QBiotics
QBiotics has successfully raised a total of $98.07M across 3 strategic funding rounds. The most recent funding activity was a Series C round of $64.42 million completed in June 2021. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 3
- Last Round Series C — $64.4M
-
First Round
First Round
(01 Jun 2016)
- Investors Count 1
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jun, 2021 | Amount | Series C - QBiotics | Valuation | TDM Growth Partners |
|
| Feb, 2020 | Amount | Series B - QBiotics | Valuation |
investors |
|
| Jun, 2016 | Amount | Series B - QBiotics | Valuation |
investors |
|
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in QBiotics
QBiotics has secured backing from 1 investor, including venture fund investors. Prominent investors backing the company include TDM Growth Partners. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Growth capital is offered by TDM Growth Partners.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by QBiotics
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - QBiotics
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Qbiotics Comparisons
Competitors of QBiotics
QBiotics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Jazz Pharmaceuticals, Zoetis, Ceva, C4 Therapeutics and Erasca, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Novel biopharmaceutical medicines are developed for unmet medical needs.
|
|
| domain | founded_year | HQ Location |
Animal medicines, vaccines, and diagnostics are manufactured and supplied.
|
|
| domain | founded_year | HQ Location |
Animal health therapeutics are developed and supplied globally by Ceva.
|
|
| domain | founded_year | HQ Location |
Small-molecule drugs for cancer treatment are developed via Degronimid platform.
|
|
| domain | founded_year | HQ Location |
Small molecule therapeutics for cancer treatment are developed.
|
|
| domain | founded_year | HQ Location |
Cancer therapies are developed using selective pathway inhibitors.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Qbiotics
Frequently Asked Questions about QBiotics
When was QBiotics founded?
QBiotics was founded in 2000 and raised its 1st funding round 16 years after it was founded.
Where is QBiotics located?
QBiotics is headquartered in Brisbane, Australia. It is registered at Brisbane, Queensland, Australia.
Who is the current CEO of QBiotics?
Victoria Gordon is the current CEO of QBiotics. They have also founded this company.
Is QBiotics a funded company?
QBiotics is a funded company, having raised a total of $98.07M across 3 funding rounds to date. The company's 1st funding round was a Series B of $22.1M, raised on Jun 01, 2016.
What does QBiotics do?
QBiotics is engaged in the discovery and development of novel cell signaling small molecules for challenging medical conditions. The company operates in the healthcare sector, specializing in oncology and wound healing solutions. Its lead oncology drug, Tigilanol Tiglate, is in clinical Phase II trials for soft tissue sarcomas and head and neck cancers. Additionally, EBC-1013 is being developed for chronic and acute wounds, with a Phase I trial planned. Veterinary oncology product STELFONTA is commercialized for mast cell tumors in dogs. Innovation is driven by proprietary platforms like EcoLogic and phenotypic screening, leveraging Australias tropical rainforest molecular diversity.
Who are the top competitors of QBiotics?
QBiotics's top competitors include Jazz Pharmaceuticals, Zoetis and C4 Therapeutics.
What products or services does QBiotics offer?
QBiotics offers Tigilanol Tiglate, EBC-1013, and STELFONTA.
Who are QBiotics's investors?
QBiotics has 1 investor. Key investors include TDM Growth Partners.
Book a demo & talk to our team
Share a few details and we’ll reach out to schedule a session.